Hope is the Air We Breathe
New Guidelines for Early Diagnosis and Treatment of Lymphangioleiomyomatosis
Download the full LAM Clinical Practice Guidelines here.
Lymphangioleiomyomatosis - or LAM - is a rare lung disease that usually strikes women during the prime of their lives. With the release of new clinical guidelines comes better understanding for the appropriate treatment of this debilitating illness, for both healthcare providers and patients alike. With this greater understanding comes greater hope for a cure. Just as air is vital to life, guidelines for diagnosis and treatment are vital to those living with LAM – and to the physicians working to treat them.
Top Five Things to Know:
- LAM patients with abnormal or declining lung function should be treated with sirolimus.
- LAM patients with problematic chylous effusions can begin sirolimus treatments prior to and/or as an alternative to invasive surgical management.
- Doxycycline is not recommended as a treatment for LAM.
- Hormonal therapy is not recommended as a treatment for LAM.
- VEGF-D testing is recommended for patients whose CT scan shows cystic abnormalities characteristic of LAM, to assist with diagnosis.
ATS/JRS LAM Clinical Practice Guidelinesplus